Increased H. pylori stool shedding and EPIYA-D cagA alleles are associated with gastric cancer 1 in an East Asian hospital 2 3 Short title: H. pylori and cagA quantification in stomach and stool 4 5 ABSTRACT 18 Background: Helicobacter pylori infection induces chronic inflammation and tissue damage in 19 the stomach, increasing risk for gastric cancer. Paradoxically, these tissue alterations may 20 promote loss of H. pylori infection during cancer progression. H. pylori's role in cancer 21 progression beyond initiation is unclear. Geographic variation in gastric cancer risk has been 22 attributed to variation in carriage and type of the H. pylori oncogene cagA. Methods: To 23 investigate possible differences in H. pylori load in the stomach and shedding in stool, H. pylori 24 load and cagA genotype were assessed using droplet digital PCR assays on gastric mucosa 25 and stool samples from 49 urea breath test-positive individuals, including 25 gastric cancer and 26 24 non-cancer subjects at Henan Cancer Hospital, Henan, China. Results: Quantitation of H. 27
INTRODUCTION 38
The bacterial pathogen Helicobacter pylori infects the human stomach causing chronic 39 inflammation of the gastric mucosa. Most infected individuals remain asymptomatic but a subset 40 develop peptic ulcers, gastric adenocarcinomas, and mucosa-associated lymphoid tissue 41 (MALT) lymphoma resulting from the infection. Disease risk depends on the severity and 42 distribution of inflammation in the stomach. Those with inflammation that is predominantly in the 43 antrum of the stomach are at higher risk for duodenal ulcer and those with inflammation that 44 extends into the stomach corpus are at higher risk for gastric adenocarcinoma (1). In those who 45 eventually develop gastric adenocarcinoma, H. pylori-induced chronic inflammation initiates a 46 pathological cascade that progresses from atrophy to intestinal metaplasia and dysplasia (2) . 47
Density of H. pylori infection has been found to be correlated with level of inflammation (3, 4) but 48 loss of H. pylori infection has been observed in atrophic gastric tissue (5) and increased pH in 49 the stomach can promote growth of other bacteria (6) . Notably, H. pylori often cannot be 50 detected within tumors and the association of H. pylori with cancer was strongest when H. pylori 51 infection was assessed 10 years prior to cancer diagnosis (7) . 52
Bacterial genetic factors contribute in part to differences in bacterial density, 53 inflammation, and disease development. The strain-variable cagA gene is associated with a 54 higher risk of gastric adenocarcinoma development (8) . The cagA gene is located within the cag 55 pathogenicity island that encodes a Type IV secretion system which delivers the CagA effector 56 protein into host gastric epithelial cells (9) . Inside the host cell, the CagA protein is 57 phosphorylated at EPIYA sites and the phosphorylated form is able to deregulate normal 58 cellular signaling (10) (11) (12) (13) . The cagA gene is grouped into two different allele types, Western 59 alleles that encode an EPIYA-C motif and East Asian alleles that encode an EPIYA-D motif. 60 cagA alleles having an EPIYA-D motif are predominantly found in H. pylori strains circulating in 61
East Asian countries and are associated with an increased risk of gastric cancer development 62 compared to cagA alleles having an EPIYA-C motif (14) . 63
Studies investigating the role of the cagA gene in density of H. pylori infection in the 64 stomach have produced conflicting results, with some studies reporting a significantly higher 65 density of H. pylori infection in those with cagA-positive H. pylori (3, 15) and some finding no 66 difference in bacterial density between cagA-positive and cagA-negative strains (4, 16, 17) . We 67 recently reported development of a new, non-invasive method for detection, quantification, and 68 cagA genotyping of H. pylori from stool samples that uses droplet digital PCR (ddPCR). We tested this method using a collection of matched serum and stool samples from volunteers in 70 Costa Rica and observed a two log range of H. pylori loads in the stool. Furthermore, the H. 71 pylori load in the stool was significantly higher in those with a cagA-positive strain (18). 72
However, the extent to which the H. pylori load in the stool reflects the load in the stomach is not 73
clear. 74
To assess differences in H. pylori carriage and colonization density upon cancer 75 development and to examine factors that contribute to the observed variability in H. pylori loads 76 in stool, including H. pylori load in the stomach and cagA status, we applied the quantitative 77 ddPCR assays to gastric mucosal brushing samples and stool samples collected from gastric 78 cancer and non-cancer subjects from China. 79
80

MATERIALS AND METHODS 81
Study Populations and Specimen Collection 82
To investigate possible differences in H. pylori carriage and load in the stomach as well as H. 83 pylori shedding in stool, C14 urea breath test (UBT, Haidewei HUBT-01P) was used to screen 84 individuals to be treated for gastric cancer or undergoing upper GI endoscopy for other 85 indications at Henan Cancer Hospital between 2015.10.27-2016.03.15. Subjects who were H. 86 pylori-positive by UBT were offered participation in this research study and all participants 87 provided written informed consent prior to participation. Participating subjects had gastric 88 mucosal brushings collected and were asked to fill out a questionnaire that covered 89 demographic characteristics, medical conditions, and medications and provide a stool sample. 90
All procedures were approved by the Henan Cancer Hospital Medical Research Institution 91
Review Board (doc # 2016oct005). 92
In total, samples were collected from 50 subjects including 25 gastric cancer subjects diagnosed 93 by pathology who were undergoing gastric resection surgery and 25 non-cancer subjects with 94 no history of gastric tumor or surgery who were undergoing upper GI endoscopy either as 95 indicated because of symptoms or as asymptomatic volunteers. All non-cancer cases showed 96 histologic evidence of gastritis and no ulcers. All 50 subjects had not taken antibiotics for gastric 97 disease in the past month. 98
Gastric mucosal brushing samples were collected from two different anatomical sites in 99 the stomach, the antrum and the corpus, using cytology brushes (Puritan Medical Products Co 100 LLC). Gastric mucosal brushings were collected and stored in a cryovial containing 1 ml flow 101 media (minimal essential media plus 10% DMSO, 5% fetal calf serum, 5mM HEPES (19) . 102
Cryovials containing the gastric mucosal brushing samples were immediately placed and kept at 103 -80°C. The gastric mucosal brushings were collected from the gastric cancer subjects during the 104 gastric resection surgery and from non-cancer subjects during upper GI endoscopy. Stool 105 samples were collected 1-2 days before either surgery or endoscopy. Participants undergoing 106 surgery collected the stool sample at the hospital and participants undergoing endoscopy 107 collected the stool sample at home and delivered it to the hospital on the same day. Stool 108 samples were collected by the participants into a vial containing 5 ml RNAlater nucleic acid 109 preservative (Ambion) and were frozen at -20°C upon receipt. In addition to the gastric mucosal 110 brushings and stool samples, gastric biopsies were collected for histological analysis. A gastric 111 biopsy was collected from the antrum and the corpus. Gastric biopsies were formalin-fixed and 112 paraffin-embedded prior to histological analysis. 113
DNA Extraction 114
For the gastric mucosal brushings, sample media and brush were transferred from the cryovial 115 to a microcentrifuge tube and centrifuged, followed by removal of the supernatant and brush. 116 DNA was then extracted from the pellet using the UltraClean Tissue and Cells DNA Isolation Kit 117 (MoBio) according to the manufacturer's instructions. 118
Stool samples were first transferred to a microcentrifuge tube and centrifuged to remove 119 the RNAlater. DNA was then extracted using the QIAamp Stool DNA Mini Kit (Qiagen) 120
according to the manufacturer's instructions, with the lysis step performed at 95°C. Stool DNA concentration was measured using a NanoDrop 2000 UV-Vis Spectrophotometer (Thermo 122 Scientific), and the concentration was adjusted to 100 ng/µl. 123
Droplet Digital PCR 124
H. pylori-specific droplet digital PCR (ddPCR) assays (H. pylori 16S assay, cagA detection 125 assay, and cagA EPIYA typing assay) were performed using the QX200 ddPCR System 126 (BioRad) as described previously (18) for stool DNA and gastric mucosal brushing DNA. Briefly, 127 each 20 µl reaction contained 1x ddPCR Supermix for Probes (BioRad), 900 nM of each primer, 128 250 nM of probes, and 10 µl DNA. Reactions were subject to thermal cycling with the following 129 conditions: 95°C for 10 minutes, 45 cycles of 94°C for 30 seconds and 55°C for 1 minute, and a 130 final incubation at 98°C for 10 minutes. Data were analyzed using the QuantaSoft software 131 version 1.6.6 (BioRad). The threshold was set to 4500 for the H. pylori 16S assay and 5500 for 132 the cagA detection assay. For the cagA EPIYA assay, the thresholds were set to 4000 (both 133 gastric and stool samples) for the FAM channel and 2500 (gastric samples) or 3000 (stool 134 samples) for the HEX channel. A positive control (stool DNA from an H. pylori-positive 135 volunteer) and negative control (molecular grade water) were included in each batch of samples 136
analyzed. 137
For the gastric brushing samples, the copy number of H. pylori 16S was normalized to 138 the copies of human DNA in the sample, as measured by a ddPCR assay for 18S. The following 139 primers and probe were used in the 18S assay: 18SFor (5' -CGATGCTCTTAGCTGAGTG -3'), 140 18SRev (5' -CTTAATCATGGCCTCAGTTC -3'), and 18S_HEX (5' hexachloro-fluorescein -141 CCGCAGCTAGGAATAATGGAATAG -black hole quencher 3'). Reactions were subject to 142 thermal cycling with the following conditions: 95°C for 10 minutes, 45 cycles of 94°C for 30 143 seconds and 59°C for 1 minute, and a final incubation at 98°C for 10 minutes. Data were 144 analyzed using the QuantaSoft software version 1.6.6 (BioRad) and the threshold was set to 145
146
The concentration of the gastric mucosal brushing DNA sample was adjusted so that the 147 copy number of the ddPCR assay target was within the dynamic range of the assay. DNA 148 samples were run as either undiluted or diluted 1:10, 1:100, 1:1000, or 1:10,000. Stool DNA 149 concentration was adjusted to 100 ng/µl as needed so that no more than 1 µg stool DNA was 150 added to each ddPCR reaction. 151
Histological Analysis 152
For histological analysis of the gastric biopsies, slides were made from formalin-fixed paraffin- were analyzed and scored as either normal (0), mild (1), moderate (2), or marked (3) (20). For the non-cancer subjects, more than one anatomical 158 site of the stomach was analyzed for a patient (i.e. antrum and corpus) and the H. pylori density, 159 neutrophils, mononuclear cells, and intestinal metaplasia was scored as the average of the two 160 sites. Atrophy was scored separately for the antrum and corpus. For the gastric cancer subjects, 161 only gastric tissue from the carcinoma adjacent site was scored. 162
Statistical Analysis 163
Correlation between gastric cancer and cagA allele was assessed using Fisher's Exact Test. 164
The Wilcoxon Two-Sample Exact Test was used for comparisons of H. pylori loads between 165 gastric cancer subjects and non-cancer subjects and between East Asian cagA allele and 166
Western cagA allele groups. Correlation between H. pylori load in the gastric mucosal brushing 167 samples from different anatomic sites and with H. pylori load in the stool was analyzed using 168 Spearman Correlation Coefficients with Fisher's z-Transformation. All statistical analyses were 169 performed in SAS version 9.4 (SAS Institute, Inc.). 170
171
RESULTS
Gastric Cancer cases show frequent evidence of active H. pylori infection 173
Of 58 gastric cancer subjects screened for H. pylori infection by UBT, 25 (43%) were H. pylori-174 positive. Of 108 non-cancer subjects screened, 25 (23%) were H. pylori-positive by UBT. One of 175 the 25 participating non-cancer subjects did not provide an adequate stool sample and was 176 excluded from the analysis. The remaining 49 subjects included in our study had a median age and chronic inflammation respectively, tended to be lower in the gastric cancer subjects, but 186 distribution of scores for atrophy, intestinal metaplasia, and H. pylori density were similar 187 between gastric cancer subjects and non-cancer subjects ( 
Cancer and non-cancer cases show similar loads of H. pylori in the stomach by ddPCR 198
To investigate the load of H. pylori in the stomach among subjects, we employed ddPCR to 199 measure the copy number of the H. pylori 16S ribosomal RNA gene, a highly conserved gene 200 present in all H. pylori strains, in total DNA extracted from mucosal brush samples from both the 201 antrum and corpus for each subject. H. pylori load was normalized to the human 18S ribosomal 202 RNA gene copy number present in each sample. The H. pylori 16S gene was detected in one or 203 both gastric mucosal brushing samples of 22 (88%) of 25 gastric cancer subjects and all 24 204 (100%) non-cancer subjects. One non-cancer subject had H. pylori 16S detected in the sample 205 from the corpus but not the antrum. Of the three subjects that did not have H. pylori detected by 206 histology, one also did not have the H. pylori 16S gene detected by ddPCR in either gastric 207 sample. The other two had low loads of H. pylori 16S detected by ddPCR (gastric H. pylori load 208 of 10 and 0.4 16S copies per 1000 18S). As shown in Figure 1A , the load of H. pylori detected 209 in gastric samples varied over several logs in both cancer and non-cancer subjects. For the 210 gastric samples with detectable H. pylori 16S, the H. pylori 16S copy number per 1000 18S 211 ranged from 0.003 to 1034 with a median of 144 for the antrum and ranged from 0.84 to 1967 212 with a median of 103 for the corpus. The H. pylori load in the antrum and corpus were 213 significantly correlated (Spearman Correlation Estimate = 0.7, 95% CI: 0.5 -0.8, Figure 1B) and 214 for subsequent analysis we considered the gastric load to be the average of that measured for 215 the antrum and corpus sample for each subject. The gastric H. pylori load between the gastric 216 cancer cases (median=139 H. pylori 16S copies per 1000 18S copies, range 0.9 -386) and the 217 non-cancer subjects (median=114 H. pylori 16S copies per 1000 18S copies, range 0.4 -1150) 218
was not significantly different (p=0.4, Wilcoxon Exact Test). intestinal metaplasia phenotype as consequence of H. pylori induced inflammation has been 238 suggested to favor outgrowth of other bacterial species over H. pylori. We saw similar 239
proportions of intestinal metaplasia in cancer cases compared to non-cancer subjects (Table1). 240
We thus checked whether gastric H. pylori load differed according to presence of intestinal 241 metaplasia (Fig. 1C) , but saw no significant difference (p=0.3, Wilcoxon Exact Test). 242 243
Stool-based ddPCR detection of H. pylori 16S is sensitive, but shows little correlation 244 with gastric load 245
We next examined the relationship between detection and copy number of the H. pylori 246 16S ribosomal RNA gene by ddPCR in stool with detection and copy number in the stomach. Of 247 the stool samples from gastric cancer cases, the H. pylori 16S gene was detected in 21 (84% of 248 the 25 gastric cancer cases). Considering the 22 gastric cancer cases for which we detected the 249 H. pylori 16S gene in the stomach, 21 (95%) also had detection in the stool. The H. pylori 16S 250 gene was detected in 22 (92%) of the 24 stool samples from non-cancer subjects. For the stool 251 samples with detectable H. pylori 16S, the H. pylori 16S copy number per µg stool DNA ranged from 2 to 1080 with a median of 26 (Figure 2A) . The H. pylori load in the stool was significantly 253 higher (Wilcoxon Exact Test, p= 0.03) in the gastric cancer cases (median=46 H.pylori 16S 254 copies per µg stool DNA, range 0 -560) compared to the non-cancer subjects (median=7.5 255 H.pylori 16S copies per µg stool DNA, range 0 -1080). The H. pylori load observed in the stool 256 was only weakly correlated with the H. pylori load in the gastric samples of the same subject 257 (Spearman Correlation Estimate = 0.3, 95% CI:0.03 -0.6, Figure 2B ). Previous studies suggest very high prevalence of cagA-positive strains and a predominance of 272
East Asian EPIYA alleles in China (21) Of these seven samples, five were determined by sequencing to have EPIYA-C (Western cagA 280 allele) and two had neither EPIYA-D nor EPIYA-C. The five that were negative for the cagA 281 EPIYA typing ddPCR assay but were determined to have EPIYA-C by sequencing all had the 282 same three nucleotide differences in the forward primer region that could explain failure of the 283 assay for these samples. One subject was determined to have an East Asian allele in the 284 corpus sample by the cagA EPIYA typing ddPCR assay and an allele having neither an EPIYA-285 D nor an EPIYA-C in the antrum sample by sequencing. 286
Combining the results of the cagA EPIYA typing ddPCR assay and sequencing for the 287 46 subjects, 32 (70%) had the East Asian allele, 10 (22%) had a Western allele, one had only a 288 non-East Asian, non-Western allele, and three were not determined. Being infected with an H. 289 pylori strain with the East Asian cagA allele was significantly associated with gastric cancer 290 (Fisher's Exact Test, p = 0.03) ( Table 2 ). Since we observed higher H. pylori loads in the stool 291 among gastric cancer cases, we examined the relationship between H. pylori load in the stool 292 and cagA allele. The median H. pylori stool load for subjects with an East Asian cagA allele was 293 33.5 H. pylori 16S copies per µg stool DNA (range 0 -560) and for subjects with a Western 294 cagA allele was 15.5 H. pylori 16S copies per µg stool DNA (range 0 -1080) (Wilcoxon Exact 295 Test p = 0.26). 296 We extended our analysis of cagA genotypes by running the cagA EPIYA ddPCR typing assay 305 on stool samples from 48 subjects. For one endoscopy case, there was insufficient stool DNA to 306 run our cagA EPIYA ddPCR assay. We detected cagA in stool for 23/31 (73%) of subjects 307
where we detected EPIYA-D type cagA in the stomach and 4/5 (80%) of subjects where we 308 detected EPIYA-C type cagA in the stomach by the cagA EPIYA ddPCR assay. In all cases we 309 detected the same EPIYA type in the stomach and stool samples by the cagA EPIYA ddPCR 310 assay. 311
312
DISCUSSION 313
In this study, we leveraged recently developed ddPCR-based quantitative assays to explore 314 differences in H. pylori load present in the stomach and shed into stool among cancer and non-315 cancer cases undergoing surgery or upper GI endoscopy respectively at a hospital in China's 316
Henan province, a region with high incidence of stomach cancer (38.13 per 100,000). At 317 present, all methods for detecting active H. pylori infection (UBT, histology, PCR, culture) have
